Also listed on Theravance, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Dec 13, 2026 · Medium confidence
20-year base term ended Mar 9, 2026
Mar 9, 2006
Dec 13, 2026
Feb 19, 2013
This patent's term runs 279 days past its 20-year base term on prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees are recorded paid; no more fees are due. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 9, 2006, when application 11/371,445, the earliest non-provisional in its chain, was filed (this one was filed Jun 17, 2010); a parent in its chain could not be resolved (the next row) | Mar 9, 2026 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +279 days, USPTO patent term adjustment record | Dec 13, 2026 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,242,137) | resolves to Dec 13, 2026, no earlier than this term, so no change | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Dec 13, 2026 | Medium confidence |
This family
| Application 11/371,445 | Abandoned not computed | not computed |
| US 8,242,137 | In force no later than Feb 2027 | no later than Feb 2027 |
| US 8,377,965 | this patent Dec 2026 | Dec 2026 |
| US 8,921,395 | Term ended Mar 2026 | Mar 2026 |
| US 9,249,099 | Term ended Mar 2026 | Mar 2026 |
| US 9,656,993 | Term ended May 2026 | May 2026 |
| US 10,577,347 | Term ended May 2026 | May 2026 |
| US 11,390,603 | Term ended Mar 2026 | Mar 2026 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jun 3, 2014 Reel 33127, frame 174 | Theravance, Inc. | Theravance Biopharma R&D IP, LLC | Assignment of Assignor's Interest |
| Sep 24, 2026 Reel 76134, frame 790 | Theravance Biopharma R&D IP, LLC | U.S. Bank Trust Company, National Association | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 8,242,137, ends no earlier than this term, so it caps nothing.